Table 3 Univariable and multivariable analysis for overall survival in patients with stage IIB NSCLC

Presence of CH (VAF ≥ 2.0%)

2.11 (1.21–3.69)

0.009*

1.71 (0.93–3.14)

0.057

Adjuvant therapy

 Done vs. not done

1.04 (0.65–1.70)

0.853

Presence of CH* adjuvant therapy

2.42 (1.54–3.81)

 < 0.001*

1.19 (1.00–1.41)

0.041*

Age (years)

1.04 (1.01–1.06)

0.010*

1.03 (1.00–1.06)

0.048*

History of smoking

1.30 (0.82–2.03)

0.244

Sex (male)

1.30 (0.82–2.05)

0.259

The number of comorbidities

 1 vs. 0

1.01 (0.64–1.60)

0.960

 ≥ 2 vs. 0

0.89 (0.46–1.72)

0.730

Pulmonary function

 FEV1 < 60%

0.53 (0.13–2.14)

0.370

 DLCO < 60%

2.90 (1.45–5.81)

0.003*

1.02 (1.37–5.65)

0.005*

EGFR mutation

 No vs. yes

1.03 (0.62–1.72)

0.913

 Unchecked vs. yes

1.32 (0.79–2.22)

0.294

Histologic structure

 SqCC vs. ADC

1.09 (0.69–1.72)

0.703

 Others vs. ADC

0.82 (0.33–2.06)

0.674